Latest news with #TermsofUs
News18
6 days ago
- Sport
- News18
Lungi Ngidi Overtakes Dale Steyn, Becomes SA's 3rd Highest Wicket-Taker In T20Is
Last Updated: South Africa's Lungi Ngidi surpasses Dale Steyn to become the third-highest wicket-taker for the Proteas in T20Is with 65 wickets in 45 matches. South Africa pacer Lungi Ngidi has surpassed the legendary Dale Steyn to become the third-highest wicket-taker for the Proteas in T20Is after claiming a wicket in the second match of the Tri-Series against New Zealand on Wednesday. Ngidi surpassed Steyn by dismissing New Zealand opener Tim Seifert, who was looking in good form before miscuing a pitch in the third over. Ngidi's slower cutter deceived Seifert, resulting in a catch by Senuran Muthusamy. Ngidi now has 65 wickets in T20 internationals, achieving this milestone in 45 matches, two fewer than Steyn who accomplished it in 47 matches. Leading the list is left-arm wrist spinner Tabraiz Shamsi with 89 wickets from 70 matches, followed by Kagiso Rabada with 71 wickets in 65 games. Bowler Matches Wickets Tabraiz Shamsi 70 89 Kagiso Rabada 65 71 Lungi Ngidi 45 65 Dale Steyn 47 65 Imran Tahir 35 61 What Happened In South Africa Vs New Zealand? In the match, South Africa won the toss and elected to field. New Zealand lost two wickets in the powerplay, with Seifert dismissed for 22 runs off 16 deliveries and his opening partner Devon Conway following shortly after. A half-century from Tim Robinson and a significant innings from Bevon Jacobs helped New Zealand reach 173-5 in their 20 overs, thanks to a crucial partnership between Tim Robinson and Bevon Jacobs. In response, South Africa struggled with the bat. Chasing 174 for victory, South Africa began brightly through Lhuan-dre Pretorius, who played a lively cameo of 27. However, his dismissal triggered a collapse, with the Proteas slipping to 62/5 by the ninth over. Dewald Brevis and George Linde both contributed brisk 30s to revive hopes, but their untimely dismissals stalled the momentum. Gerald Coetzee fought valiantly towards the end, but the target proved too steep. South Africa were eventually bowled out for 152 with 10 balls remaining, giving New Zealand a confident start to the series. Matt Henry and Jacob Duffy spearheaded the bowling attack with three wickets each, while Ish Sodhi contributed with two, and James Neesham added one. Mitchell Santner showcased a moment of brilliance in the field to dismiss Rassie van der Dussen. Despite solid spells from Kwena Maphaka and Senuran Muthusamy, South Africa could not avoid their first loss of the tournament. They now have one win and one defeat, while New Zealand start strong with a victory. New Zealand had kicked off their Tri-Series campaign with a composed and clinical performance, securing a 21-run victory over South Africa. view comments First Published: July 16, 2025, 20:23 IST Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.
News18
11-07-2025
- Business
- News18
Glenmark Pharma Soars 10% To Record High After AbbVie Cancer Drug Deal; Details
Last Updated: Shares of Glenmark Pharmaceuticals Ltd surged 10 per cent in early trade on Friday; Key points for investors Glenmark Share Price: Shares of Glenmark Pharmaceuticals Ltd surged 10 per cent in early trade on Friday, scaling a new all-time high of Rs 2,094 apiece, after the company announced a major licensing agreement involving its innovation subsidiary. In a regulatory filing post market hours on July 10, Glenmark said its step-down wholly-owned subsidiary, Ichnos Glenmark Innovation (IGI), had signed a global licensing pact with AbbVie. The investigational drug, ISB 2001, is currently undergoing Phase 1 clinical trials for patients with relapsed or refractory multiple myeloma, a form of blood cancer. Under the terms of the agreement, AbbVie will obtain exclusive rights to develop, manufacture, and commercialize ISB 2001 across key developed markets, including North America, Europe, Japan, and China. Glenmark will retain commercialization rights across emerging markets such as the rest of Asia, Latin America, Russia/CIS, the Middle East, Africa, Australia, New Zealand, and South Korea. Glenmark's IGI Therapeutics SA will receive an upfront payment of $700 million and may earn up to $1.225 billion in additional milestone payments tied to development, regulatory clearances, and commercial success. The deal also includes tiered, double-digit royalties on net sales. The US FDA granted ISB 2001 orphan drug designation in July 2023 and fast-track designation in May 2025 for treating relapsed or refractory multiple myeloma. These designations are expected to speed up the drug's development and approval process. Roopal Thakkar, M.D., EVP of R&D and Chief Scientific Officer at AbbVie, said, 'Multispecifics, including trispecific antibodies, are a new frontier in immuno-oncology. This partnership underscores our commitment to advancing novel treatments for multiple myeloma, where unmet medical needs still exist." Cyril Konto, M.D., President and CEO of IGI, added, 'ISB 2001 showcases the power of our BEAT® protein platform to create next-generation multispecifics™. This agreement is a defining moment in IGI's journey and accelerates the drug's path to patients." Stock Performance and Analyst Take Glenmark Pharma shares have surged over 14% in the past five sessions, 28% in one month, and more than 51% over the past year. Despite the rally, Nomura has maintained a 'Neutral' rating on the stock with a price target of Rs 1,500, implying over 21% downside from its previous close of Rs 1,904. The brokerage noted that the deal is the largest licensing agreement signed by an Indian pharmaceutical firm and exceeded its expectations in value. view comments First Published: July 11, 2025, 10:41 IST Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.
News18
09-07-2025
- Business
- News18
Affidavit Filing Must Be Transparent: Allahabad HC Restores Registry's Powers, Caps Fee At Rs 125
Last Updated: The court noted that while the HC bar associations in Allahabad and Lucknow had accepted the Rs 125 fee structure, discrepancies were observed in the receipts issued at both The Allahabad High Court has upheld the registry's authority to mark defects in affidavits sworn before notaries and directed the bar associations at both Allahabad and Lucknow to ensure strict compliance with the court's photo affidavit procedure, including transparent fee collection. A division bench of Justices Attau Rahman Masoodi and Shree Prakash Singh modified a prior direction that barred the Stamp Reporting Section from flagging defects in notarised affidavits. Citing Chapter II, Rule 1(ii) of the Allahabad High Court Rules, the court held that such affidavits are not exempt from scrutiny and that the Registry retains its power to point out defects and allow rectification. 'Such a direction does not stand in consonance with the relevant rule," the bench observed. The judgment also addressed discrepancies in the implementation of the office memorandum dated 22.11.2024, which mandates that every affidavit be accompanied by a passport-size photograph and a unique identification number issued by the respective bar association for a fixed charge of Rs 125. While the memorandum clearly prohibits charging more than Rs 125 without prior approval, the court found that at Allahabad, a single receipt was being issued for both the prescribed affidavit fee and an additional Rs 475 welfare contribution, making the payment appear compulsory. At Lucknow, receipts failed to specify the Rs 125 amount at all. Calling this a violation of the memorandum's intent, the court directed both bar associations to remodel their receipts within a period of 15 days, ensuring that procedural charges are clearly distinguished from voluntary welfare contributions. 'No litigant for institution of the proceedings before this court is compelled to deposit any amount higher than what is prescribed in the aforesaid office memorandum dated 22.11.2024," the HC observed. The high court further reaffirmed that bar associations are free to run welfare schemes, but such initiatives must remain voluntary and independent of mandatory filing procedures. The controversy originated after the writ court, in a previous judgment, issued directions concerning the affidavit filing process without hearing the high court bar association, which later challenged the observations. The special appeal sought to address procedural lapses and protect the autonomy of bar associations in administering identity protocols while ensuring that litigants are not burdened with non-transparent or compulsory charges. view comments First Published: July 10, 2025, 03:12 IST Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.
